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Abstract
Generation and interpretation of biotransformation data on drugs, i.e. identification of physiologically relevant metabolites,
defining metabolic pathways and elucidation of metabolite structures, have become increasingly important to the drug
development process. Profiling using
14Co r
3H radiolabel is defined as the chromatographic separation and quantification
of drug-related material in a given biological sample derived from an in vitro, preclinical in vivo or clinical study. Metabolite
profiling is a very time intensive activity, particularly for preclinical in vivo or clinical studies which have defined limitations
on radiation burden and exposure levels. A clear gap exists for certain studies which do not require specialized high volume
automation technologies, yet these studies would still clearly benefit from automation. Use of radiolabeled compounds in
preclinical and clinical ADME studies, specifically for metabolite profiling and identification are a very good example. The
current lack of automation for measuring low level radioactivity in metabolite profiling requires substantial capacity,
personal attention and resources from laboratory scientists. To help address these challenges and improve efficiency, we
have innovated, developed and implemented a novel and flexible automation platform that integrates a robotic plate
handling platform, HPLC or UPLC system, mass spectrometer and an automated fraction collector.
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Introduction
Generation and interpretation of biotransformation data on
drugs, i.e. identification of physiologically relevant metabolites,
defining metabolic pathways and elucidation of metabolite
structures, have become increasingly important to the drug
development process as well as more visible to health authorities
(HA). Since the introduction of the FDA metabolite in safety
testing ‘‘MIST’’ guidance and the International Conference on
Harmonization (ICH) metabolite guidance M3, early information
on metabolites structures and their systemic exposure is of high
relevance [1,2].
Profiling using
14Co r
3H radiolabel is defined as the
chromatographic separation and quantification of drug-related
material in a given biological sample derived from an in vitro,
preclinical in vivo, or clinical study. Initial metabolite profiling data
from biotransformation studies are often generated in a high
throughput manner during the discovery phase of pharmaceutical
development. However, this data has limitations as it is semi-
quantitative in nature and is based mostly on mass spectrometric
response factors [3,4]. Metabolite profiling data generated during
early and late stage development phase requires accurate methods
of quantification of metabolites in circulation and excreta. The
profiled chromatographic peaks are also characterized structurally
using analytical techniques such as mass spectrometry or in some
cases even NMR. Thus, linking the structural data with the
profiled data, a metabolism pathway can be elucidated on
a quantitative level.
Radiolabeled (
14Co r
3H-labeled) compounds can be used for
accurate quantification, and offer advantages that eliminate the
need for sample calibration curves as well as in certain cases
providing a signature isotope distribution pattern (
14C) that aids in
the MS identification of metabolites. Chromatographically sepa-
rated metabolites which contain the radiolabel derived from the
parent compound are quantitated through radioactive decay (b-
emission). Radioactive decay can either be counted (detected)
using on-line scintillation radioflow detectors (RFD) or off-line
microplate scintillation counters (MSC), which count fractionated
samples using well plate format, e.g. Topcount [5–7].
For preclinical in vivo or human ADME, international guidance
set clear limits on radiation burden and exposure levels [8]. In the
cases where low levels of radioactivity must be administered, the
on-line radio detection method often does not provide sufficient
detection sensitivity and quantification (lower limit of quantifica-
tion (LLOQ): 100–500 dpm or 0.8–4 pmol) [9]. Thus, off-line
counting is necessary due to the requirements of a much lower
(LLOQ: 2–5 dpm or 16–40 fmol), which is achieved by a much
higher signal to noise ratio generated from longer data acquisition
times than compared to on-line counting [9]. In context of
a collected chromatographic peak over separate wells, off-line
detection would be in the range 10–20 fold more sensitive than on-
line detection.
Metabolite profiling by conventional HPLC often requires long
chromatographic run times ranging between 90 to 120 min per
sample injection. High-performance liquid chromatography
(HPLC) coupled to RFDs is an established and robust method
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39070to separate and detect radiolabeled drug metabolites. Recent
chromatography developments that favor smaller particle chro-
matography (,2 mm) has led to increased use of ultra-perfor-
mance liquid chromatography (UPLC).
UPLC coupled with high resolution and fast scanning mass
spectrometers has been demonstrated to be a robust, efficient for
drug metabolite separation and identification [6,7]. However,
UPLC coupled with RFDs has significant limitations for metab-
olite quantification, which arises from resolution and sensitivity
loss due to the eluant-scintillant mixing processes occurring in the
flow cell [5].
UPLC coupled with MSC, e.g. TopCount, has been successfully
applied to both identification and quantification of metabolite
while preserving chromatographic resolution [5,10]. This combi-
nation offers advantages of higher sensitivity and resolution
compared to the traditional on-line approach, i.e. HPLC with
RFDs. Specifically, the narrow peak widths and longer counting
times allow accurate profiling and measurement of samples
containing low concentrations of drug-related material. Unlike
RFDs, MSC systems are not limited by residency times and allow
longer counting times. Representative counting times for MSC are
2–5 min per well compared to RFD cell counting times of 7–10 s.
For MSC, there is a trade-off for resolution versus sensitivity, i.e.
increasing the number of fractionated wells will increase resolu-
tion, but will in turn result in lower sensitivity. MSC is a robust
Figure 1. Schematic of the interfaced instruments: HPLC (Agilent)/UPLC (Waters), robotic plate handler (PlateCrane) robot, fraction
collector (Gilson) and mass spectrometer (Waters).
doi:10.1371/journal.pone.0039070.g001
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separations.
Some limitations exist for the HPLC/UPLC coupled to a MSC.
One limitation is the inherent delay between sample injection and
data viewing and processing. Another limitation is the longer
counting durations required for sample measurements, which can
serve either as an advantage or a disadvantage. To further reduce
analysis times, microplate imagers (Viewlux) have been shown to
reduce data acquisition times for 384 well plate counting in
comparison to TopCount [11]. Lastly, manual plate handling and
changing prior to scintillation counting still remains a very time
intensive step even though chromatographic run times may be
significantly reduced using UPLC with off-line radioactivity
microplate imagers. Assuming HPLC run times of 90 minutes,
only 2–3 samples could be processed per day as the collected
fraction plates must be constantly changed manually.
To address the manual plate handling limitation and automate
the process to increase throughput, we developed and implemen-
ted a novel automation technology by linking two separate
technologies designed for two different applications. Specifically,
a robotic plate handling platform was linked to a fraction collector,
a HPLC or UPLC with UV detection, and a mass spectrometer.
Materials and Methods
Materials
Solvent and chemical materials used for this project were
Uvasol
TM spectrometry grade acetonitrile (Merck, Darmstadt,
Germany), LC-MS grade water (Fisher Scientific, Leicestershire,
UK), formic acid puriss p.a.; ,98% (T) (Fluka Analytical,
Germany) and ammonium formate Ultra $99.0% (NT) (calc.
based on dry substance) (Fluka Analytical, Germany). The
scintillation material used for this project was LumaPlates yttrium
silicate scintillation-coated 96 well plates (Packard BioScience,
Groningen, Netherlands).
Biological materials used for this project were human plasma
and dog urine. Human plasma samples were taken from healthy
volunteers after administration of a Novartis development
compound (NVP123) which was in accordance to study protocol.
The clinical part of the study was performed in accordance with
Good Clinical Practice guidelines and the Declaration of Helsinki
(1964 and subsequent revisions). All subjects gave written informed
consent before entering the study. The protocol and the radio-
safety assessment were approved by the local Basel, Switzerland
ethics committee, and the Swiss federal Office of Public Health
(Radioprotection Division in Bern, Switzerland), respectively.
With Owner’s and Study Director’s consent, dog urine samples
were taken in accordance with international guidelines and Swiss
law for animal welfare. Specifically, all experiments were carried
out in accordance with authorization guidelines of the Swiss
Federal and Cantonal veterinary offices for care and use of
laboratory animals. The animal experimental authorization
number is ‘‘17 (17-Nov-2008) Kantonales Veterina ¨ramt Basel’’.
Sample Preparation
The absorption, distribution, metabolism and excretion of
[
14C]-NVP123 were investigated in four healthy male volunteers
after a single oral dose of 200 mg with a radioactive dose of
1.61 MBq. The whole body radiation dose estimation was less
than 1.0 mSv.
Metabolite profiling was determined in plasma, urine and feces
matrices. For plasma, individual samples of subjects taken at the
same time post-dose were analyzed to establish the pharmacoki-
netics. For feces and urine, each subject was pooled across the
collection period of 0–96 hours. Sample workup and processing in
each matrix, e.g. extraction, drying and reconstitution, are
described in the following paragraphs. Note, the dog urine sample
was collected, processed and analyzed in a similar manner as
described for the human urine below. In total, 300 [
14C]-NVP123
samples (preclinical and clinical) were collected and analyzed using
this automation platform.
Plasma aliquots (4 mL) were weighed in 50 mL BD FalconTM
tubes and extracted with 30 mL of acetonitrile (UvasolTM Merck,
Darmstadt, Germany). Samples were stirred, chilled for 30 min-
utes at 4uC, and subsequently centrifuged at 40006 g for
10 minutes. The supernatant was removed and the resulting
pellet was reconstituted by sonication for 15 min in 10 mL water/
acetonitrile (1:5, v/v). The resulting suspensions were chilled for
30 min at 4uC, and then centrifuged at 80006g for 10 minutes.
The combined supernatants were evaporated to dryness under
a stream of nitrogen at room temperature. The remaining residues
were reconstituted in water (0.2 mL) then transferred into
a 1.5 mL ultracentrifuge tubes (Beckman, Krefeld, Germany).
The supernatants obtained were separated from the pellets then
transferred into a HPLC vial, from which the tare weight was
previously determined. The solutions were concentrated under
nitrogen to approx. 100 mL. After addition of 25 mLo f
acetonitrile, the concentrates were completed with water up to
approx. 0.25 g and aliquots of 80 mL were injected on the HPLC
component of the automation platform described below.
Urine for each subject was pooled across the collection period of
0–96 hours. Aliquots of 1 mL were centrifuged at 100006 g for
15 minutes and stored at 220uC until HPLC analysis. Aliquots of
100 mL of supernatants were directly injected on the HPLC
component of the automation platform described below.
Feces homogenates (diluted with water) of each subject were
pooled across the collection period of 0–96 hours. An aliquot of
approx. 0.6 mL of each pool were mixed with 10 mL acetonitrile.
The suspensions were stirred for 60 minutes at room temperature
followed by centrifugation for 15 minutes at 100006 g. After
removal of the supernatants, the residues were extracted a second
time with 1 mL water and 10 mL acetonitrile, using the same
procedure. Both supernatants were combined, and evaporated to
dryness under a stream of nitrogen at room temperature. The
residues were reconstituted by addition of acetonitrile (100 mL)
and water (900 mL). Aliquots of 100 mL were injected on HPLC
component of the automation platform described below.
Figure 2. The robotic plate handler coupled to fraction
collector.
doi:10.1371/journal.pone.0039070.g002
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An Agilent 1200 HPLC (Agilent Technologies, Waldbronn,
Germany) equipped with two binary pumps, Degasser, ALS
Thermostat, a CTC PAL Autosampler (CTC Analytics, Zwingen,
Switzerland) was used for HPLC method coupled to PlateCrane
(Hudson Robotics Inc, Springfield, USA).
Hplc parameters. Guard column: Atlantis dC18,
2062.1 mm, 3 mm particles, (Waters, Baden-Da ¨ttwil, Switzer-
land).
Analytical column 1: Atlantis dC18, 15062.1 mm, 3 mm
particles, (Waters, Baden-Da ¨ttwil, Switzerland).
Temperature of guard column and analytical column: 40uC.
Figure 3. Plate movement sequence by robotic plate handler for a single chromatographic run.
doi:10.1371/journal.pone.0039070.g003
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sample loop.
Flow: 350 ml/min.
Mobile phase A: ammonium formate 20 mM, with 0.1 % of
formic acid; pH 3.6 B: acetonitrile.
HPLC-Gradient: 0–35 min 10–25% B, 35–60 min 25–50% B,
60–65 min 50–90% B, 65–70 min 90% B, 70–72 min 90–10% B,
72–90 min 10% B.
An Acquity UPLC system (Waters, Milford, USA), equipped
with two binary pumps, column manager, Degasser, PDA
detector, and a CTC PAL Autosampler (CTC Analytics, Zwingen,
Switzerland) was used for UPLC method.
Uplc parameters. Guard column: Acquity UPLC HSS T3
C18 Van Guard Pre-Column, 2.165 mm, 1.8 mm particles,
(Waters, Baden-Da ¨ttwil, Switzerland).
Analytical column: Acquity UPLC HSS T3 C18, 15062.1 mm,
1.8 mm particles, (Waters, Baden-Da ¨ttwil, Switzerland).
Temperature of guard column and analytical column: 40uC.
Sample injection (default): 20 to 100 mL injected via a 200 mL
sample loop.
Flow: 500 ml/min.
Mobile phase A: ammonium formate 20 mM, with 0.1 % of
Figure 4. Plate stacking sequence by robotic plate handler for a programmed sequence of chromatographic runs.
doi:10.1371/journal.pone.0039070.g004
Figure 5. Sequential workflow for sample processing and
analysis, from initiation to completion.
doi:10.1371/journal.pone.0039070.g005
Table 1. Calculated time for current and streamlined
processes.
Without
PlateCrane With PlateCrane
Step in process hours WD hours WD
Sample preparation 8 2 8 2
Chromatographic run time 8 4 24 1
a)
Plate drying 8 2
b) 24 1
c)
TopCount measurements 24 4.5
d) 24 4.5
d)
Total time 12.5 8.5
*Assumption: 10 samples, 8 collected plates per sample and a chromatographic
run time of 90 minutes.
hours – # work hours per day; WD – # work days required for each step.
doi:10.1371/journal.pone.0039070.t001
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Gradient: 0–17 min 10–25% B, 17–30 min 25–50% B, 30–
32 min 50–90% B, 32–35 min 90% B, 35–36 min 90–10% B, 36–
45 min 10% B.
Mass spectrometry parameters. Both LC Systems were in
line with a Synapt Quadrupole-time-of-flight tandem mass
spectrometer (Waters, Manchester, UK) and a GX271 fraction
collector (Gilson, Villiers-le-Bel, France) with Plate Crane EX
(Hudson Robotics Inc., Springfield, USA). The Agilent LC system
was controlled by ChemStation B.03.02 (Agilent Technologies,
Waldbronn, Germany) The UPLC and MS Systems were
controlled by MassLynx V4.1 (Waters, Manchester UK). The
fraction collector was controlled by Trilution V1.4 LCOK8197
(Gilson, Villiers-le-Bel, France), and the Plate Crane by SoftLinx
V3.10 (Hudson Robotics Inc., Springfield, USA).
After the chromatography the effluent was split into a ratio of
1:8 with the smaller portion directed into the electrospray LC-MS
interface and the bigger part was used for offline radio detection
(metabolites pattern).
MS spectra with accurate mass measurement for [
14C]-NVP123
were obtained by LC-MS on Synapt Q-TOF (Waters, Manchester
UK) in positive electrospray mode. Capillary voltage 3 kv, Cone
voltage 20 V, scan range m/z 100–1000. MS spectra were
acquired in MS
E mode. The reference channel of the LockSpray
interface was operated with a solution of reserpine (575 ng/mL) in
acetonitrile at a flow rate of 5 mL/min. During data acquisition
from the reference channel, the cone voltage was set to 40 V. The
[M+H]
+ ion of reserpine at m/z 609.2812 was used as lock mass
for recalibrating the spectra to obtain exact mass data.
Figure 6. Reconstructed HPLC radiochromatogram of [
14C]-NVP123 and its metabolites from human plasma. Note, ‘‘M#’’ (e.g. M13)
denotes a designated metabolite number, which is not assigned based on order of chromatographic elution.
doi:10.1371/journal.pone.0039070.g006
Figure 7. Reconstructed UPLC radiochromatogram of [
14C]-NVP123 and its metabolites from dog urine. Note, ‘‘M#’’ (e.g. M13) denotes
a designated metabolite number, which is not assigned based on order of chromatographic elution.
doi:10.1371/journal.pone.0039070.g007
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tograms and integrated using an internal Novartis Nitisc program
(Version V12). Standard chromatographic peak integration
software would also be suitable for these purposes.
Set-up of PlateCrane robot and Gilson fraction
collector. The PlateCrane robot and Gilson fraction collector
with custom programmed firmware provided by Gilson were
mounted on a movable table with lockable castors. The robotic
arm of the PlateCrane was programmed and synchronized so that
it does not to collide with arm of Gilson fraction collector. Also,
the positioning of Luma microplates in Gilson fraction collector
was programmed to ensure the most efficient sampling. The entire
Figure 8. Representative mass spectrometric structure elucidation of [
14C]-NVP123 and its resulting metabolites M1/M2, M3 and
M7. (x in structure denotes truncation).
doi:10.1371/journal.pone.0039070.g008
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PlateCrane and Gilson fraction collector. The CTC autosampler
triggered the start of the LC-MS and the fraction collector. The
PlateCrane was initiated and controlled by the Gilson Trilution
software. Custom programming scripts were created by Hudson
and Gilson engineers. The PlateCrane should be placed in close
proximity to the LC-MS system to minimize chromatography
delay and peak broadening. An illustration and photo of
instrumental set-up are shown in Figure 1 and 2.
For the PlateCrane, a maximum of 10 ‘‘stack columns’’ are
available (Figure 1). Each stack column can hold up to 24 Luma
plates. Stack columns 1–5 are reserved for ‘‘empty’’ plates and
stack columns 6–10 for ‘‘filled’’ plates. Based on current set up,
a maximum of 120 plates can be automatically collected with
PlateCrane. The chronological sequence for picking up and
placing plates from stack columns can be customized and
programmed according to experiment. In principle, the system
could almost double its capacity by reprogramming to accommo-
date 216 plates. The 9 stack columns would be loaded with empty
plates while one stack column would contain no plates. The one
empty stack column would be loaded with filled plates, which
would eventually generate another stack column with no plates.
This has not been done as no more 120 plates have been exceeded
in an automation sequences to date.
The PlateCrane and fraction collector software was pro-
grammed that for both 96 or 384 well Luma plates where
a maximum of 8 plates can be used within a single chromato-
graphic run. As a note, the fraction collector can hold a maximum
of 2 Luma plates on deck in position 1 and 2 (Figure 1)
A chronological outline describing the automation
process: (Figures 3 and 4). Before any sample injection, all
methods and sequences need to be programmed on the HPLC,
Gilson fraction collector and MS instruments.
1. The Gilson fraction collector is first initiated from software
(Trilution) and commands the PlateCrane robotic arm to pick
up a 96 or 384 well plate from stack 1 and place it in position of
plate 1. After completion of this task, the Trilution software is
ready to receive start signal via contact closure from
autosampler. The MS sequence list is then initiated from the
MS software (MassLynx). The MS system is now awaiting
a trigger signal from the HPLC autosampler.
2. Once sample has been injected by the HPLC autosampler,
a contact closure signal simultaneously triggers MS acquisition,
UV detector (if programmed), and the fraction collector, which
has now started HPLC eluant collection. Ten seconds after the
initial fractions were collected, the fraction collector requests
a ‘‘Ready’’ signal from PlateCrane. The Platecrane responds
‘‘Ready Yes’’. Then robotic arm picks-up a second empty
Luma plate from stack 1 and places it on deck of fraction
collector in position 2.
3. After collection of first Luma plate has been completed,
fraction are automatically continued to be collected on second
plate. Ten seconds after starting collection on second Luma
plate, the PlateCrane requests pick-up of filled plate number 1
from deck of fraction collector. The robotic arm picks up filled
plate number 1 and places it in stack 6. The PlateCrane
automatically picks up an empty plate from stack 1 and places
it on the deck of fraction collector in position 1. After the
second Luma plate in position 2 has been filled completely,
fraction collection continues automatically on third plate in
position 1 on the deck of fraction collector. For changing the
third and the fourth plate within this run, the same process is
followed as described in step 3.
4. After last Luma plate has been collected the robotic arm places
the filled plate in stack 6 and new plate from stack one is placed
in position 1 on deck and robotic arm goes to ‘‘Home’’ position
and awaits the trigger signal from next injection.
5. For each injected sample in the programmed sequence, steps 2
and 3 are repeated. Throughout the automation, the
PlateCrane takes empty Luma plates in sequential order from
stack columns 1–5, and places subsequently filled plates in the
empty stack columns 6–10 respectively.
6. After last plate in the sequence has been collected signal ‘‘End
sequence’’ is sent to PlateCrane. The PlateCrane then places
last plate in stack and Trilution software does not demand for
new plate. The robotic arm moves in ‘‘Home’’ position.
7. After collection of plates and the ‘‘automation’’ process is
complete. The plates are either under vacuum centrifugation
using a Speedvac AES1010 (Savant Instruments Inc., Hol-
brook, USA), or air dried in fume hood for 2 h. The dried
plates are heat sealed and loaded on Topcount instrument for
radioactivity measurements.
Topcount radioactivity measurements. The dried scintil-
lation plates were analyzed in a microplate scintillation counter
(TopCount NXT; Packard Instruments, Meriden, CT, US). In
order to optimize TopCount performance, counting heads
(photomultipliers) were reconditioned and then closely matched
with one another in terms of tolerances and specifications (TopLab
GmbH, Switzerland). The matched heads were then (re)installed
in the TopCount instrument. Counting times were between
365 min to 3640 min, depending on the amounts of radioactivity
injected. Counts were monitored during the three counting
periods were averaged unless one of the three measurements was
an outlier in the positive direction (possibly due to an electrostatic
discharge), in which case only the counts from the two remaining
counting periods were averaged. Moreover, a correction was made
for the different background levels of the 12 photomultipliers of
the microplate scintillation counter.
Figure 9. Overview of representative biotransformation reac-
tions for [
14C]-NVP123. (x in structure denotes truncation).
doi:10.1371/journal.pone.0039070.g009
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Automation technologies and processes are well established and
specifically tailored for high throughput ADME-related screening
during the drug discovery phase. However, high volume
automation platforms often do not translate well for applications
which are not screening type assays, nor are high volume
platforms designed for these purposes. Thus, a clear gap exists
for such studies which do not require specialized high volume
automation technologies, yet these studies would still clearly
benefit from automation. In vitro, preclinical in vivo and human
ADME studies conducted during the drug development phase
which have a metabolite identification component coupled with
radioactivity measurements are a good example.
To address this gap and increase throughput for metabolite
identification in ADME studies using Topcount measurement, the
PlateCrane was coupled to fraction collector as described in the
experimental section. This ‘‘hybrid’’ system allows continuous
changing of fraction collected plates (maximum 120 plates) which
drastically reduced manual 96-and 384 well plate collection and
handling. A schematic description of system configuration is
shown in Figure 1 and a photo of the system is shown in Figure 2.
The automated plate changing process and sequence is shown in
Figure 3 and 4. These steps are detailed within the experimental
section.
The PlateCrane and Gilson fraction collector components are
mounted on movable table with lockable castors, which allows
flexibility of use in different labs. This ‘‘hybrid’’ system allows
continuous changing of fraction collected plates. Chromatographic
sample output can be increased up to 10 (and more depending run
time) samples per day on a 24/7 basis. This technology was
successfully implemented and supported a human ADME study
for a designated Novartis development compound ([
14C]-
NVP123) that required metabolite profiling and identification.
A general workflow process for metabolite identification with
and without PlateCrane is illustrated in Figure 5. The manual
plate changing step denoted in Figure 5 is one rate limiting step in
the process. Furthermore, Table 1 highlights time differences for
different steps in process with and without PlateCrane. For
example, an analysis of 8 samples with Platecrane results in a time
savings of 4 days as compared to without PlateCrane. Moreover,
the number of samples injected within one day could be increased
up to 10 fold as this system is able to constantly change plates
throughout the night and over the weekends while left unattended
(Table 1). Overall, the net benefit was about a 32% increase in
productivity when all steps were counted in the workflow (Figure 3
& Table 1).
A typical reconstructed HPLC metabolic profile of [
14C]-
NVP123 in human plasma acquired with described automation
set-up is shown in Figure 6. The gross sample analysis time for this
complex ADME study was completed 4 months sooner compared
to similar studies using conventional methods (without Plate-
Crane). Studies using conventional methods currently take about
one year for completion. Thus, the time savings from this set-up
has a substantial positive impact on the development program of
drug. Integration of UPLC-MS with PlateCrane and Gilson
Fraction collector exemplifies the flexible nature of this evolving
platform. Chromatographic run times could be shortened from
90 minutes down to 30 min. The narrow peak widths and longer
counting times available from UPLC combined with TopCount
provides a more sensitive method of profiling drug metabolites in
complex biological samples, particularly when samples contain low
concentrations of drug-related material. Figure 7 shows a chro-
matogram of [
14C]-NVP123 in dog urine. The narrow peak
widths and shorter chromatographic run times available from
UPLC combined with TopCount provide a more sensitive method
of profiling drug metabolites in complex biological samples,
particularly when samples contain low concentrations of drug-
related material.
In addition, MS spectra for metabolite identification data can be
collected in parallel, i.e. the same way as done for HPLC-MS
using a RFD. Note, the MS data generated for structure
elucidation using PlateCrane automation was compared and
obviously confirmed to be identical with the MS data generated
using the prior method of manual injection (MS data or structures
not shown). Figure 8 shows the structure elucidated by mass
spectrometry for [
14C]-NVP123, M1/M2, M3 and M7 metabo-
lites. All the metabolite structures listed in the chromatograms
(Figure 6 & 7) have also been elucidated by mass spectrometry and
then confirmed using co-chromatography and MS with authentic
standards where applicable. Figure 9 shows a biotransformation
overview resulting from the example study, which used the robotic
plate handling platform, HPLC / UPLC system, mass spectrom-
eter and the automated fraction collector.
The focus of Figures 6, 7, 8, and 9 is to fully highlight the
representative types of data output generated from this combina-
tion platform (automated fractionation and plate handling,
chromatography, and MS structural characterization with pro-
posed fragmentation schemes). Full structures will be shown in
a separate publication which will be dedicated to interpretation
and results of the project itself, and not the automation platform.
Thus, partial structures fulfilled these purposes and were shown for
this reason.
Conclusions
This novel linked automated system significantly increases
throughput for preclinical and clinical ADME studies. The plate
changing process has now been automated, and time for manual
sample manipulation has been significantly reduced. This tech-
nology drastically reduced manual 96-well/384-well plate collec-
tion and handling as a maximum of 120 plates could be collected
automatically. Sample analysis of [
14C]-NVP123 for the presented
human ADME study including data analysis and reporting was
completed faster, i.e. in about 8 months as compared to one year.
Throughput in preclinical and clinical ADME studies has clearly
benefited from this new technology, and this has positive impact
on accelerating drug development studies. In summary, a major
limiting step or ‘‘bottle neck’’ has essentially been eliminated from
the process. A remaining limiting step is long sample counting
times that may be required by MSCs. A potential future
application of this automation platform could also be the
chromatographic separation and isolation of metabolites on
a preparative scale.
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